Midnight has extended its sharp rally as strong investor demand pushed the token to a new all-time high. The project associated with Cardano founder Charles HoskinsonMidnight has extended its sharp rally as strong investor demand pushed the token to a new all-time high. The project associated with Cardano founder Charles Hoskinson

Cardano’s Midnight Token Hits New All-Time High Amid a 50% Rally

Midnight has extended its sharp rally as strong investor demand pushed the token to a new all-time high. The project associated with Cardano founder Charles Hoskinson continues to attract attention after sustaining upside momentum. 

While NIGHT has already delivered outsized gains, technical and macro signals suggest additional upside potential remains.

Midnight Holders Are Watching A New Sunrise

Investor support for NIGHT remains firm. The Chaikin Money Flow sits in positive territory above the zero line, confirming net inflows. Although the indicator dipped slightly over the past 48 hours, capital continues entering the asset, signaling ongoing confidence rather than distribution.

Much of this demand is linked to Midnight’s association with Charles Hoskinson, the founder of Cardano. That connection has boosted credibility and visibility.

In the short term, this narrative-driven interest is likely to keep capital rotating into NIGHT, supporting elevated price levels.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

NIGHT CMFNIGHT CMF. Source: TradingView

Macro conditions also favor NIGHT’s performance. The token shows a weak correlation with Bitcoin, insulating it from broader market uncertainty. This independence has allowed NIGHT to trend higher even as Bitcoin struggles to regain momentum.

Low correlation often benefits emerging assets during periods of BTC consolidation. With Bitcoin lacking a clear recovery signal, NIGHT’s ability to move on its own fundamentals remains a key advantage. This dynamic could continue supporting relative outperformance in the near term.

NIGHT Correlation To BitcoinNIGHT Correlation To Bitcoin. Source: TradingView

NIGHT Price Forms New All-Time High

Midnight price surged 42.7% over the past 24 hours, trading near $0.093 at the time of writing. The rally resulted in a new intraday all-time high of $0.096. Momentum remains strong, reflecting aggressive buying and sustained interest following the breakout.

Bullish sentiment and favorable macro conditions support further upside. If current trends persist, NIGHT could push beyond the $0.100 level. Entering the 10-cent range would mark a psychological milestone, potentially drawing additional speculative interest and reinforcing momentum.

NIGHT Price Analysis. NIGHT Price Analysis. Source: TradingView

Risks remain if holders begin taking profits. A wave of selling could pull NIGHT back toward the $0.075 support. Losing that level would weaken the bullish structure. Further downside could extend to $0.060, invalidating the current bullish thesis and increasing volatility.

Market Opportunity
TokenFi Logo
TokenFi Price(TOKEN)
$0.003976
$0.003976$0.003976
-4.16%
USD
TokenFi (TOKEN) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26